Pyxis Oncology, Inc. 8-K

What Happened

• Pyxis Oncology, Inc. announced (filed an 8-K) that on June 30, 2026 it entered a Securities Purchase Agreement for a private placement to institutional and accredited investors. The company agreed to sell 19,600,153 shares of common stock at $2.551 per share and issued common warrants to purchase an equal number of shares. The expected upfront gross proceeds are approximately $50.0 million (before fees and expenses); closing was expected on July 2, 2026. Wells Fargo Securities acted as placement agent.
• The Common Warrants carry a $3.289 exercise price, become exercisable on the earlier of (a) public disclosure of clinical data from the MICVO Phase 1 monotherapy study in 2L+ recurrent/metastatic head and neck squamous cell carcinoma or (b) October 1, 2026, and expire July 2, 2029. If all warrants are exercised for cash, Pyxis would receive an additional ~ $64.0 million. The company said the upfront proceeds are expected to extend its cash runway into the second quarter of 2027 and support advancement of its MICVO clinical program.

Key Details

• Shares offered: 19,600,153 common shares at $2.551 per share (gross ≈ $50.0M upfront).
• Warrants: equal number of common warrants, $3.289 exercise price, exercisable by earlier of clinical-data disclosure or Oct 1, 2026; expire July 2, 2029; full exercise would add ≈ $64.0M.
• Timing & agent: Securities Purchase Agreement dated June 30, 2026; expected close July 2, 2026; placement agent Wells Fargo Securities, LLC (company to pay customary fees and expenses).
• Registration rights: Pyxis agreed to file a registration statement covering resale of the shares and warrant shares by no later than Oct 2, 2026, with specified effectiveness deadlines and customary indemnities and liquidated damages for registration failures.
• Disclosure: Company issued a press release on June 30, 2026 announcing the transaction.

Why It Matters

• Financing impact: The transaction provides immediate near-term capital (~$50M) to fund the company’s lead clinical program (MICVO) and push toward planned clinical milestones, while potentially bringing another $64M if investors exercise the warrants.
• Dilution risk: The issuance increases outstanding share count now and could further dilute shareholders if warrants are exercised; exercise price and timing are specified and tied partly to clinical-data events.
• Liquidity for investors: Registration rights obligate Pyxis to register the sold securities for resale, enabling purchasers to potentially sell shares in the public market once the registration is effective.
• Operational focus: Funds are explicitly intended to advance MICVO development; investors should monitor clinical-data announcements (which can trigger warrant exercisability) and updates on cash runway and clinical progress.